Skip to main content

Table 4 Sensititvity analysis: mean costs/ cost differences depending on management of local relapse, given in € (2015)

From: Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck

 

IMRT

IMRT + C12

difference

mean total costs (€)

re-RT always as IMRT

  mean unadjusted

15,078.-

29,636.-

14,558.-

  mean adjusted (3 monthly intervals)

15,204.-

31,859.-

16,655.-

  mean adjusted annually

12,066.-

30,108.-

18,042.-

  mean adjusted, 3.5% discount

11,635.-

28,558.-

16,923.-

  mean adjusted 3.0% discount

11,694.-

28,758.-

17,065.-

mean total costs (€)

re-RT always as C12

  mean unadjusted

24,570.-

36,554.-

11,984.-

  mean adjusted (3 monthly intervals)

25,058.-

41,745.-

16,687.-

  mean adjusted annually

18,707.-

39,272.-

20,565.-

  mean adjusted, 3.5% discount

17,810.-

36,050.-

18,240.-

  mean adjusted 3.0% discount

17,931.-

36,459.-

18,528.-